Solid tumor
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, and the expected survival time is greater than 3 months; 2. Patients with histologically proven indications of carrelizumab; 3. ECOG (Eastern Cooperative Oncology Group) score 0-2 points; 4. The investigator determines that it can benefit from carrelizumab treatment; 5. The patient voluntarily joined the study and signed an informed consent form (InformedConsentForm, ICF); 6. Those who are expected to have good compliance can follow up the efficacy and adverse reactions according to the requirements of the plan.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Known to be allergic to carrelizumab for injection or pharmaceutical excipients, or have a severe allergic reaction to other monoclonal antibodies; 3. Known human immunodeficiency virus (HIV) positive test history or known acquired immunodeficiency syndrome (AIDS); 4. Suffer from any active autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy); 5. Active hepatitis B (HBVDNA >= 2000IU/ml); 6. Use of immunosuppressive drugs within 14 days before the first use of the study drug, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (ie not more than 10 mg/day of prednisolone or equivalent physiological doses Other corticosteroids); 7. Vaccination with live attenuated vaccine within 4 weeks before the first administration or planned during the study period; 8. Complicated with severe infection within 4 weeks before the first administration (such as: intravenous infusion of antibiotics, antifungal or antiviral drugs), or unexplained fever > 38.5 degrees C during the screening period/before the first administration; 9. There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the research, or interfere with the results of the research, and patients who the researcher believes are not suitable for participating in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactZhu Chunrong
The First Affiliated Hospital of Soochow University
Outcome results
None listed